Related Experiment Video

Updated: Jul 4, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Regulators of chemokine receptor activity as promising anticancer therapeutics

Konstantin V Balakin1, Yan A Ivanenkov, Sergey E Tkachenko

  • 1ChemDiv, Inc., San Diego, CA 92121, USA. kb@chemdiv.com

Current Cancer Drug Targets
|June 10, 2008
PubMed

Insights

Chemokines and their receptors are key regulators in cancer, influencing tumor-infiltrating leukocytes and tumor progression. Small-molecule agents targeting chemokine receptor pathways offer promising therapeutic strategies for cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Chemokines are small proteins that direct cell migration via chemokine receptors, impacting biological and pathological processes.
  • They act as proinflammatory mediators, controlling leukocyte migration and neovascularization, and are implicated in inflammatory diseases and viral infections.
  • Chemokines and receptors are produced by tumor cells, suggesting roles in tumorigenesis and the tumor microenvironment.

Purpose of the Study:

  • To review key aspects of chemokine signaling in cancer.
  • To elucidate clinically relevant strategies for modulating chemokine receptor activity in cancer treatment.
  • To highlight research strategies for designing chemokine receptor-targeted therapeutics.

Main Methods:

  • Literature review of chemokine signaling pathways.
  • Analysis of therapeutic strategies targeting chemokine receptors.
  • Examination of research approaches for small-molecule agent development.

Main Results:

  • Chemokines and receptors are overexpressed in tumors, regulating tumor-infiltrating leukocytes and crucial activities like angiogenesis and metastasis.
  • Modulation of chemokine receptor pathways shows promise for treating inflammatory diseases and viral infections.
  • Small-molecule agents and targeted therapeutics are being developed to exploit these pathways in cancer treatment.

Conclusions:

  • Chemokine signaling plays a critical role in cancer progression and the tumor microenvironment.
  • Targeting chemokine receptors with small-molecule agents represents a promising therapeutic avenue for cancer.
  • Further research into chemokine receptor targeted therapeutics is essential for advancing cancer treatment.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System10:25

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Published on: September 20, 2019

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...